Ruxolitinib
Small molecule targets JAK1, JAK2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | OPZELURA | — | 2022-07-18 – 2025-09-18 | fda.gov ↗ |
| Label expansions (8) | US (FDA) | JAKAFI | — | 2013-06-12 – 2022-12-19 | fda.gov ↗ |
| Approved | EU (EMA) | Jakavi | — | 2012-08-23 | europa.eu ↗ |
| Approved | US (FDA) | JAKAFI | — | 2011-11-16 | fda.gov ↗ |
Trials 343 · started per year
Also used as a comparator or background therapy in 63 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04744116 Background | Feb 2021 → Mar 2032 expected | acute graft versus host disease, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT07521046 Background | Aug 2026 → Aug 2029 expected | myelofibrosis | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07340138 Background | Apr → Nov 2026 expected | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06233110 Background | Oct 2025 → Jan 2029 expected | chronic graft versus host disease | Stefanie Sarantopoulos, MD, PhD. | Recruiting | No outcome recorded |
| Phase 1 | NCT06508463 Background | Jan 2024 → Dec 2028 expected | anaplastic large cell lymphoma, mycosis fungoides, peripheral T-cell lymphoma, not otherwise specified | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05936359 Background | Sep 2023 → Feb 2028 expected | myeloproliferative neoplasm | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT05371964 Background | May 2022 → Feb 2027 expected | myelofibrosis | Geron Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT05088356 Background | Sep 2021 → May 2028 expected | acute leukemia, chronic myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome | Stanford University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04328844 Background | Feb 2020 → Dec 2023 overdue | myelofibrosis, non-Hodgkin lymphoma, non-small cell lung carcinoma, uveal melanoma | iOnctura | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03373877 Background | May 2018 → Oct 2019 | myelofibrosis, primary myelofibrosis | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03386214 Background | Apr 2018 → Sep 2021 | myelofibrosis | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03515200 Background | Apr 2018 → Jul 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT02960945 Comparator | Nov 2016 → Jan 2017 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02593760 Background | Jan 2016 → Mar 2017 | myelofibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02436135 Background | Jun 2015 → Nov 2017 | myelofibrosis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT06887803 Background | Nov 2025 → Mar 2028 expected | myelofibrosis | iOnctura | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06909136 Background | Jul 2025 → Oct 2027 expected | myelofibrosis | Suzhou Junjing BioSciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06327100 Background | Aug 2024 → May 2029 expected | myelofibrosis, primary myelofibrosis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05280509 Background | Jun 2022 → Oct 2025 overdue | myelofibrosis, primary myelofibrosis | Telios Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04485260 Background | Jan 2021 → Oct 2022 | myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04354727 Background | Dec 2020 → Dec 2022 | myelofibrosis | Ascentage Pharma Group Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04581954 Comparator | Oct 2020 → Nov 2022 | COVID-19, pneumonia | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT04176198 Background | Dec 2019 → Apr 2027 expected | myelofibrosis | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04097821 Background | Sep 2019 → May 2023 | myelofibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT02711137 Background | May 2016 → Feb 2019 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02587598 Background | Dec 2015 → Aug 2020 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07572669 Background | Sep 2025 → Mar 2027 expected | acute graft versus host disease | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06923228 Comparator | Apr → Jul 2025 | atopic eczema | CAGE Bio Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06477549 Comparator | Jun 2024 → Jun 2028 expected | acute biphenotypic leukemia, lymphoblastic lymphoma, myelodysplastic syndrome | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06457425 Comparator | May 2024 → May 2026 overdue | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05980806 Background | Apr 2024 → Jun 2027 expected | myelofibrosis, thrombocytopenia | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT06378060 Background | Mar 2024 → Apr 2026 overdue | aplastic anemia | Hematology department of the 920th hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06075706 Comparator | Nov 2023 → Feb 2026 overdue | acute graft versus host disease | medac GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05787860 Comparator | Nov 2022 → Jan 2024 | seborrheic dermatitis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT05037760 Background | Dec 2021 → Feb 2028 expected | myelofibrosis | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT04118556 Comparator | Dec 2021 → Apr 2026 | acute graft versus host disease | Mats Remberger | Terminated | No outcome recorded |
| Phase 2 | NCT03669965 Comparator | Jan 2019 → Apr 2022 | acquired polycythemia vera | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03144687 Background | Jan 2018 → Mar 2020 | myeloproliferative neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02718300 Background | Feb 2017 → Jan 2021 | myeloproliferative neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT03333187 Comparator | Dec 2016 → Oct 2024 overdue | myelofibrosis | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01981850 Background | Oct 2013 → Jul 2020 | acquired polycythemia vera, myelofibrosis, primary myelofibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01712308 Background | Feb 2013 → May 2022 | anemia, myelodysplastic/myeloproliferative neoplasm, myelofibrosis | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01369498 Background | Jun 2011 → Jun 2014 | myelofibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07366801 Comparator | Sep 2025 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06719024 Comparator | Nov 2024 → Jun 2025 overdue | vitiligo | Hospital Authority, Hong Kong | Recruiting | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07357727 Background | Jun 2026 → May 2028 expected | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07317700 Comparator | Feb 2026 → Dec 2027 expected | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06479135 Background | Jun 2024 → Dec 2026 expected | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06079879 Comparator | Dec 2023 → Jul 2027 expected | essential thrombocythemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04934670 Comparator | Jun → Nov 2022 | acute graft versus host disease | Xenikos | Terminated | No outcome recorded |
| Phase 3 | NCT04629833 Comparator | Aug 2021 → Aug 2027 expected | acute graft versus host disease | medac GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT04551053 Background | May 2021 → Aug 2023 | myelofibrosis, primary myelofibrosis | Incyte Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT04551066 Background | May 2021 → Aug 2023 | myelofibrosis, primary myelofibrosis | Incyte Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT04603495 Background | Apr 2021 → Aug 2023 overdue | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04120090 Comparator | Jul 2019 → Jul 2020 | hemophagocytic syndrome | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03165734 Comparator | Jun 2017 → Oct 2026 expected | myelofibrosis, primary myelofibrosis | Swedish Orphan Biovitrum | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02598297 Comparator | Feb 2016 → Oct 2017 | myelofibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01969838 Comparator | Dec 2013 → Sep 2016 | myelofibrosis, primary myelofibrosis | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07498205 Comparator | Aug 2026 → Aug 2029 expected | myelofibrosis | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06364319 Background | Jul 2026 → Dec 2027 expected | chronic graft versus host disease | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05039580 Background | May 2021 → Apr 2023 | Epstein-Barr virus infection | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07184853 Background | Sep 2025 → Sep 2027 expected | graft versus host disease | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04745637 Background | — | acquired polycythemia vera, acute graft versus host disease, chronic graft versus host disease, myelofibrosis with myeloid metaplasia | Novartis Pharmaceuticals | Available | No outcome recorded |
Press releases naming this drug 140 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | Incyte Corporation | Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis incyte.com ↗ |
| 2026-06-26 | Incyte Corporation | Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis incyte.com ↗ |
| 2026-05-07 | Incyte Corporation | Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis incyte.com ↗ |
| 2026-05-01 | Incyte Corporation | Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease incyte.com ↗ |
| 2025-10-25 | Incyte Corporation | Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis incyte.com ↗ |
| 2025-09-18 | Incyte Corporation | Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis incyte.com ↗ |
| 2025-06-20 | Incyte Corporation | Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis incyte.com ↗ |
| 2025-03-08 | Incyte Corporation | Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting incyte.com ↗ |
| 2024-03-10 | Incyte Corporation | Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa incyte.com ↗ |
| 2023-10-13 | Incyte Corporation | Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis incyte.com ↗ |
| 2023-10-11 | Incyte Corporation | New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients incyte.com ↗ |
| 2023-07-11 | Incyte Corporation | Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis incyte.com ↗ |
| Show all 140 releases opens the full record — a long page | ||
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 414 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ruxolitinib | “The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗398“Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.” NCT01644110 ↗ “Ruxolitinib is a Janus kinase 1/2 inhibitor that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP).” PMID 35131254 ↗ Feb 2022 “PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.” NCT05039580 ↗ “Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.” NCT07576010 ↗ “Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.” PMID 32634234 ↗ Jul 2020 “This Phase II study tests a new treatment combining two oral drugs, ruxolitinib and belumosudil, for these patients.” NCT07643025 ↗ “2. Ruxolitinib, a JAK1/2 inhibitor that can reduce inflammation by interfering with immune signaling pathways.” NCT06951971 ↗ “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines” NCT02396628 ↗ “Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.” NCT06233110 ↗ “Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles.” NCT02742324 ↗ “Ruxolitinib at a starting dose of 10mg, orally administered twice daily.” NCT05870475 ↗ “mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib” NCT03165734 ↗ “including ruxolitinib, basiliximab, or methotrexate” NCT07572669 ↗ “ruxolitinib 45 mg/day from day -12 through day -2” NCT03922724 ↗ “Romidepsin, Ruxolitinib, Sorafenib” NCT02788201 ↗ “Romidepsin Ruxolitinib Sorafenib” NCT02551718 ↗ “Ruxolitinib: up to 25 mg BD” NCT06887803 ↗ “ruxolitinib, 15 mg bid” NCT06504030 ↗ “Ruxolitinib 5mg bid” NCT06378060 ↗ “Drug: Ruxolitinib” NCT05936359 ↗ “Drug: ruxolitinib” NCT03533790 ↗ “Ruxolitinib” NCT03774082 ↗ “Ruxolitinib” NCT04370301 ↗ “Ruxolitinib” NCT02142036 ↗ |
| Known as | INC424 | “Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well established, potent and selective inhibitor of Janus kinase (JAK)1 and JAK2” NCT04359290 ↗9“The JAK1/2 kinase inhibitor Ruxolitinib (INC424) is approved for myelofibrosis.” NCT02396628 ↗ “the JAK Inhibitor Ruxolitinib (INC424)” NCT02087059 ↗ “RUXOLITINIB / INC 424” NCT02469974 ↗ “Ruxolitinib (INC424)” NCT02370706 ↗ “INC424 / Ruxolitinib” NCT04414098 ↗ |
| Known as | INCB018242 | “Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I...” NCT02041429 ↗ |
| Known as | INCB018424 | “A Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib...” NCT03954236 ↗4“Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients” NCT01340651 ↗ “Ruxolitinib (INCB018424)” NCT01594216 ↗ |
| Known as | INCB018424 phosphate | “Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well established, potent and selective inhibitor of Janus kinase (JAK)1 and JAK2” NCT04359290 ↗ |
| Known as | INCB018424 phosphate cream | “INCB018424 phosphate cream” NCT02809976 ↗1“INCB018424 Phosphate Cream” NCT06238817 ↗ |
| Known as | INCB18424 | “RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT01164163 ↗ |
| Known as | Jakafi | “Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate...” NCT05398809 ↗6“The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in...” NCT02613598 ↗ “The purpose of this study is to find out the effects of a study drug, ruxolitinib (also called Jakafi), in these patients.” NCT07085039 ↗ “Ruxolitinib (Jakafi/Jakavi) is FDA approved for myelofibrosis and was shown to reduce splenomegaly and improve symptoms.” NCT04281498 ↗ “Ruxolitinib (Jakafi) is an Food and Drug Administration (FDA) approved treatment for myelofibrosis” NCT02066532 ↗ “Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID” NCT03110822 ↗ |
| Known as | Jakavi | “The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of...” NCT02091752 ↗10“Ruxolitinib (JAKAVI®) is currently approved in the European Union (EU) for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (PMF)” NCT04359290 ↗ “Ruxolitinib (Jakafi/Jakavi) is FDA approved for myelofibrosis and was shown to reduce splenomegaly and improve symptoms.” NCT04281498 ↗ “IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.” NCT06536166 ↗ “Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)” NCT06909136 ↗ “Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg.” NCT02962388 ↗ “Prednisone + Jakavi(ruxolitinib)” NCT06756061 ↗ “Drug: Ruxolitinib (JAKAVI®)” NCT07184853 ↗ “Ruxolitinib (JAKAVI®)” NCT07366801 ↗ “Ruxolitinib (JAKAVI®)” NCT06607367 ↗ “Ruxolitinib (JAKAVI®)” NCT07464951 ↗ |
| Known as | low-dose ruxolitinib | “low-dose ruxolitinib” NCT03165734 ↗ |
| Known as | OPZELURA | “OPZELURA (Ruxolitinib) Cream” NCT06673654 ↗ |
| Known as | RUX | “Functional small-molecule screening of primary acute myeloid leukemia (AML) samples identified ex vivo synergy between the JAK1/2 inhibitor, ruxolitinib (Rux), and venetoclax...” PMID 42007254 ↗ Feb 202611“Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “The FMF-02 is a multicenter, randomized, open-label, phase IIb clinical trial to compare the safety and effectiveness of FM and ruxolitinib phosphate (RUX) in patients with...” PMID 41883618 ↗ Mar 2026 “To determine the safety and efficacy of ruxolitinib (RUX) and fostamatinib (FOS) compared with standard of care (SOC) in patients requiring hospital admission for the treatment...” PMID 41644167 ↗ Feb 2026 “Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2...” PMID 32518419 ↗ Jun 2020 “Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).” PMID 33957195 ↗ May 2021 “Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.” NCT01822756 ↗ “Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance.” PMID 36564535 ↗ Dec 2022 “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)” NCT04456634 ↗ “ruxolitinib (RUX, 5 mg/day) with corticosteroids” PMID 39438467 ↗ Oct 2024 “Ruxolitinib (Rux)” NCT06615050 ↗ |
| Known as | Ruxo | “Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.” NCT05491304 ↗ |
| Known as | Ruxolitinib cream | “Ruxolitinib cream, a Janus kinase (JAK) inhibitor, is effective and well tolerated in adolescents and adults with AD.” PMID 36586583 ↗ Dec 2022 |
| Known as | ruxolitinib phosphate | “The FMF-02 is a multicenter, randomized, open-label, phase IIb clinical trial to compare the safety and effectiveness of FM and ruxolitinib phosphate (RUX) in patients with...” PMID 41883618 ↗ Mar 202611“Determine the effect of ruxolitinib phosphate (ruxolitinib) on relapse at 1-year after autologous (auto) stem cell transplant (SCT) in T-cell lymphoma (TCL).” NCT07356245 ↗ “Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well established, potent and selective inhibitor of Janus kinase (JAK)1 and JAK2” NCT04359290 ↗ “Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia” NCT02092324 ↗ “20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)” NCT04456634 ↗ “Pelabresib monohydrate tablets + ruxolitinib phosphate tablets” NCT04603495 ↗ “Ruxolitinib phosphate tablets 5 mg administered as oral doses.” NCT00952289 ↗ “Ruxolitinib phosphate blocks a protein called janus kinase” NCT07278856 ↗ “ruxolitinib (ruxolitinib phosphate)” NCT02528877 ↗ “ruxolitinib (ruxolitinib phosphate)” NCT01732445 ↗ “Drug: Ruxolitinib Phosphate” NCT03041636 ↗ |
| Known as | Ruxolitinib, Jakafi | “Ruxolitinib, Jakafi” NCT06209606 ↗ |
| Known as | Ruxolitinib, Jakavi | “Ruxolitinib, Jakavi” NCT03110822 ↗ |
| Known as | Topical Ruxolitinib (INCB18424) | “Topical Ruxolitinib (INCB18424)” NCT06399029 ↗ |
| Action | Inhibit | “a small molecule Janus kinase 2 (JAK2)-inhibitor” NCT00639002 ↗ |
| Modality | Small molecule | “ruxolitinib, a small molecule Janus kinase (JAK) inhibitor” NCT00509899 ↗ |
| Route | Oral | “15 mg po bid” NCT00044304 ↗ |
| Target | JAK2 | “a small molecule Janus kinase 2 (JAK2)-inhibitor” NCT00639002 ↗ |